Chiesi Farmaceutici S.p.A. (Chiesi Group), the international research-focused pharmaceutical and healthcare group, announced it has entered into an agreement with Allinaire Therapeutics, LLC, a Harrington Project company founded by BioMotiv. Chiesi will acquire the world-wide rights to monoclonal antibodies (mAbs) against endothelial monocyte-activating polypeptide II (EMAP II) for treatment of Pulmonary Artery Hypertension (PAH). Harrington Discovery Institute provided the initial grant funding and therapeutic development services to Irina Petrache, MD, 2014 Harrington Scholar-Innovator at Indiana University and National Jewish Health.
”I received not only funding from Harrington Discovery Institute, but also a lot of help in how to take our approach, which is very academic, into a commercially appealing and valuable product.”
-Irina Petrache, MD
"This investment by Chiesi highlights our unique strength in drug discovery and development. We work with brilliant Scholars and a team of experts to advance treatment that targets the underlying cause of disease.”
- Jonathan S. Stamler, MD, President, Harrington Discovery Institute
Robert S. & Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation